Based on the strong demand for its COVID-19 antigen test as well as for Imaging’s consumables and the closing of the Varian acquisition, management lifted its organic sales growth assumptions as well as its EPS ones. Reported Q2 figures were in line with our expectations, but consensus was beaten by +2.4% at the top line, but missed by -4.6% on the adjusted EBIT level. The company significantly increased its operating CF due to good working capital management.